Lineage Cell Therapeutics FY2024 EPS Raised by Cantor Fitzgerald

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Analysts at Cantor Fitzgerald upped their FY2024 EPS estimates for Lineage Cell Therapeutics in a report issued on Monday, November 18th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per share of ($0.14) for the year, up from their prior estimate of ($0.18). The consensus estimate for Lineage Cell Therapeutics' current full-year earnings is ($0.12) per share.

Separately, Craig Hallum began coverage on Lineage Cell Therapeutics in a report on Tuesday, August 20th. They issued a "buy" rating and a $4.00 price target for the company.

Lineage Cell Therapeutics Trading Down 29.0 %

Shares of Lineage Cell Therapeutics stock opened at $0.64 on Thursday. The company has a market capitalization of $121.12 million, a PE ratio of -5.35 and a beta of 1.28. Lineage Cell Therapeutics has a 52-week low of $0.61 and a 52-week high of $1.61.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of LCTX. Raffles Associates LP raised its holdings in shares of Lineage Cell Therapeutics by 35.8% during the second quarter. Raffles Associates LP now owns 4,357,781 shares of the company's stock worth $4,346,000 after purchasing an additional 1,147,800 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Lineage Cell Therapeutics by 35.7% in the second quarter. Bank of New York Mellon Corp now owns 435,958 shares of the company's stock worth $435,000 after buying an additional 114,762 shares during the last quarter. Rhumbline Advisers grew its holdings in Lineage Cell Therapeutics by 15.1% during the second quarter. Rhumbline Advisers now owns 132,491 shares of the company's stock worth $132,000 after acquiring an additional 17,411 shares during the period. Price T Rowe Associates Inc. MD raised its position in Lineage Cell Therapeutics by 77.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 161,314 shares of the company's stock valued at $239,000 after acquiring an additional 70,418 shares in the last quarter. Finally, Comerica Bank lifted its holdings in Lineage Cell Therapeutics by 84,745.8% in the first quarter. Comerica Bank now owns 250,295 shares of the company's stock valued at $370,000 after acquiring an additional 250,000 shares during the period. 62.47% of the stock is owned by institutional investors and hedge funds.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.